Perrigo To Launch Private Label Mucinex, Prevacid, With An Eye On Lipitor
This article was originally published in The Tan Sheet
Executive Summary
Private label giant Perrigo is readying generic competitors to Reckitt Benckiser’s Mucinex and Takeda Pharmaceuticals’ Prevacid, CEO Joseph Papa says.
You may also be interested in...
Perrigo OTCs, Nutritionals Underperform Despite Record Overall Revenue
Perrigo delivered record first-quarter revenue but fell short of analyst expectations due to slowing growth in its consumer health care and nutritional units.
J&J Consumer Recaptures Growth, Plans To Restore Most OTCs By Mid-2012
Johnson & Johnson reported July 19 the first period of positive growth for its consumer unit in more than a year.
Perrigo's Zantac 150 Generic Marks First Approval From Remediated Plant
Perrigo will launch private-label equivalents of OTC heartburn reliever Zantac 150 this summer.